28-03-2013 дата публикации
Номер: US20130079245A1
The present invention provides compositions and their use in diagnosing ulcerative colitis, Crohn's Disease, and inflammatory bowel disease. 1. A biomarker consisting of between 2 and 35 different nucleic acid probe sets , including:(a) a first probe set that selectively hybridizes under high stringency conditions to a nucleic acid target selected from the group consisting of IGH (SEQ ID NO:11, 12, 13, 14, 15, and/or 16), MMD (SEQ ID NO:2), PDLIM1 (SEQ ID NO:3), PDIA6 (SEQ ID NO:4), CD4 (SEQ ID NO:5), DNAJA1 (SEQ ID NO:6), HBA2 (SEQ ID NO:7), RBM4 (SEQ ID NO:8), QARS (SEQ ID NO:9), WIPF1 (SEQ ID NO:10), or full complements thereof; and(b) a second probe set that selectively hybridizes under high stringency conditions to a nucleic acid target selected from the group consisting of IGH (SEQ ID NO:11, 12, 13, 14, 15, and/or 16), MMD (SEQ ID NO:2), PDLIM1 (SEQ ID NO:3), PDIA6 (SEQ ID NO:4), CD4 (SEQ ID NO:5), DNAJA1 (SEQ ID NO:6), HBA2 (SEQ ID NO:7), RBM4 (SEQ ID NO:8), QARS (SEQ ID NO:9), WIPF1 (SEQ ID NO:10), or full complements thereof,wherein the first probe set and the second probe set do not selectively hybridize to the same nucleic acid target.2. The biomarker of claim 1 , including a third probe set that selectively hybridizes under high stringency conditions to a nucleic acid target selected from the group consisting of IGH (SEQ ID NO:11 claim 1 , 12 claim 1 , 13 claim 1 , 14 claim 1 , 15 claim 1 , and/or 16) claim 1 , MMD (SEQ ID NO:2) claim 1 , PDLIM1 (SEQ ID NO:3) claim 1 , PDIA6 (SEQ ID NO:4) claim 1 , CD4 (SEQ ID NO:5) claim 1 , DNAJA1 (SEQ ID NO:6) claim 1 , HBA2 (SEQ ID NO:7) claim 1 , RBM4 (SEQ ID NO:8) claim 1 , QARS (SEQ ID NO:9) claim 1 , WIPF1 (SEQ ID NO:10) claim 1 , or full complements thereof claim 1 ,wherein none of the first probe set, the second probe set, and the third probe set selectively hybridize to the same nucleic acid target.3. The biomarker of claim 2 , including a fourth probe set that selectively hybridizes under high stringency ...
Подробнее